Bit Origin
BTOG
Bit Digital
BTBT
Bitfarms
BITF
Canaan
CAN
Coinbase
COIN
US Stock MarketDetailed Quotes
ALMS Alumis
- 4.590
- +0.050+1.10%
Close Mar 4 16:00 ET
- 4.650
- +0.060+1.31%
Post 17:30 ET
249.73MMarket Cap-1.05P/E (TTM)
4.672High4.476Low92.20KVolume4.500Open4.540Pre Close423.40KTurnover0.38%Turnover RatioLossP/E (Static)54.41MShares13.53052wk High0.72P/B111.58MFloat Cap4.36052wk Low--Dividend TTM24.31MShs Float13.530Historical High--Div YieldTTM4.31%Amplitude4.360Historical Low4.592Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Alumis Stock Forum
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Friday, 28th February at 9:08 am
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis –
– Additional Phase 2 e-poster presentations to describe patient-reported outcomes,...
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Thursday, 27th February at 4:15 pm
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ou...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
No comment yet